Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Miles

Showing results (421-430 of 501) with videos related to

Pageof 51
Sort By:
Leukemia & Lymphoma|February 20, 2019
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT studyNoemi Horvath, Andrew Spencer, Melita Kenealy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myelomaH Miles Prince, Linda Mileshkin, Andrew Roberts, et al.
JAMA|June 19, 2003
Confronting depression and suicide in physicians: a consensus statementClaudia Center, Miriam Davis, Thomas Detre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphomaMaher K Gandhi, Eleanore Lambley, Jacqueline Burrows, et al.
Internal Medicine Journal|January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupShirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Leukemia|May 24, 2020
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysisMeletios A Dimopoulos, Xavier Leleu, Philippe Moreau, et al.
Blood|July 16, 2008
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host diseaseMary E D Flowers, Jane F Apperley, Koen van Besien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphomaLeigh Ellis, Yan Pan, Gordon K Smyth, et al.
Journal of Hematology & Oncology|January 25, 2014
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Pageof 51

Showing results (421-430 of 501) with videos related to

Sort By:
Pageof 51
Leukemia & Lymphoma|February 20, 2019
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT studyNoemi Horvath, Andrew Spencer, Melita Kenealy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myelomaH Miles Prince, Linda Mileshkin, Andrew Roberts, et al.
JAMA|June 19, 2003
Confronting depression and suicide in physicians: a consensus statementClaudia Center, Miriam Davis, Thomas Detre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphomaMaher K Gandhi, Eleanore Lambley, Jacqueline Burrows, et al.
Internal Medicine Journal|January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupShirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Leukemia|May 24, 2020
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysisMeletios A Dimopoulos, Xavier Leleu, Philippe Moreau, et al.
Blood|July 16, 2008
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host diseaseMary E D Flowers, Jane F Apperley, Koen van Besien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphomaLeigh Ellis, Yan Pan, Gordon K Smyth, et al.
Journal of Hematology & Oncology|January 25, 2014
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Pageof 51